Available clinical data indicate that BCR-directed inhibitors such as SYK (fostmatinib), BTK (ibrutinib) and PKCβ (enzastaurin) are active in ≤ 20% of DLBCL patients. Here, BCR is linked to diffuse large B-cell lymphoma.